Untested combinationNo trial of a BPC-157 and TB-500 blend has been published, neither peptide is FDA-approved, and both are banned in sport.[5] The FDA has received adverse event reports involving blended products, described below.
Using a peptide calculator for blends
The calculator above handles one substance at a time. For a two-peptide vial, enter only the peptide you want to measure by:
- Amount of one peptide in the vial: the mg of that peptide alone, for example 5 for a vial labeled "5 mg + 5 mg". Do not enter the total.
- Liquid added: the full volume added to the vial.
- Amount to measure: how much of that peptide you need.
The units shown are correct for that peptide. The second peptide is in the same units, at its own concentration:
Worked example: a vial with 5 mg of each in 2 mL holds 25 mcg of each per unit. Measuring 100 mcg of the first peptide takes 4 units, and those same 4 units also hold 100 mcg of the second. If the vial were 10 mg + 5 mg instead, 100 mcg of the first would bring 50 mcg of the second.
What 10 units hold
A quick reference for equal-ratio vials. The figures are arithmetic for the stated contents; they are not doses.
| Vial | Peptide 1 (mcg) | Peptide 2 (mcg) | Total (mcg) |
|---|---|---|---|
| 2 mg + 2 mg in 1 mL | 200 | 200 | 400 |
| 2 mg + 2 mg in 2 mL | 100 | 100 | 200 |
| 2 mg + 2 mg in 3 mL | 66.7 | 66.7 | 133.3 |
| 5 mg + 5 mg in 1 mL | 500 | 500 | 1,000 |
| 5 mg + 5 mg in 2 mL | 250 | 250 | 500 |
| 5 mg + 5 mg in 3 mL | 166.7 | 166.7 | 333.3 |
| 10 mg + 10 mg in 1 mL | 1,000 | 1,000 | 2,000 |
| 10 mg + 10 mg in 2 mL | 500 | 500 | 1,000 |
| 10 mg + 10 mg in 3 mL | 333.3 | 333.3 | 666.7 |
Unequal vials work the same way: each peptide's column is its own mg ÷ mL × 100. The total column is the sum, which is the only number the calculator would show if you entered the vial's total mg, and the reason not to.
Regulatory status of blends
No BPC-157 and TB-500 blend is FDA-approved, and the 2026 HHS compounding policy excludes blends.
- Not approved. Neither peptide is FDA-approved, and the FDA evaluates each substance and each salt separately.[2][3]
- Excluded from the 2026 HHS policy. The draft enforcement-discretion policy for compounding BPC-157 and TB-500 requires that the product contain "only a single Active Pharmaceutical Ingredient". HHS says single-ingredient products make adverse events easier to attribute.[1]
- Both on FDA's safety page. FDA's wording for each peptide flags immunogenicity and impurity risks.[7] See the BPC-157 and TB-500 pages.
- Research-use sellers. FDA has warned a seller of BPC-157 and TB-500 products marketed "for research purposes only".[6]
What is known about the combination in people
Almost nothing: no trial of the blend has been published.
- No trial. We found no published trial of the blend.
- One chart review. In a retrospective review from one clinic, 4 patients received knee injections of BPC-157 together with "thymosin beta-4", form not stated. 3 of the 4 reported improvement, with no control group.[4]
- A reaction that recurred. One FDA adverse event report describes darkening of the skin and gums after a BPC-157 + TB-500 product labeled "research purposes only", injected under the skin twice daily. It came back when the product was used again.[2]
- Complaint reports. FDA's food and supplement complaint system holds 2 reports involving blended TB-500 and BPC-157.[3]
Other peptide pages
The peptides most often looked up alongside this one. Each page gives that peptide's FDA status, compounding status and published human evidence, with sources; the status table has all 23 in one place.
- BPC-157Not approved 15-amino-acid peptide. Human data: a few tiny, uncontrolled studies.
- TB-500Not approved A 7-amino-acid fragment of thymosin beta-4. No human trials of TB-500 itself.
- GHK-CuNot approved Copper peptide. Studied on skin; injectable use has no published trials.
- KPVNot approved Lys-Pro-Val tripeptide. No human data by any route.
- LL-37Not approved Human cathelicidin. Topical wound trials; FDA cites tumor concerns.
- TesamorelinFDA-approved Egrifta SV and Egrifta WR. Labeled doses, diluents and volumes.
Frequently asked questions
How do I calculate units for a BPC-157 and TB-500 blend?
Enter the mg of one peptide only (not the total) and the liquid volume. The units you get are right for that peptide. The other peptide comes along in the ratio of the two amounts on the label.
Can I measure each peptide separately from a blend?
No. Once two powders are dissolved together, every drop holds both in the same ratio. Only separate vials allow separate amounts.
Is a BPC-157 and TB-500 blend legal to compound?
Neither peptide is on the 503A bulks list. The draft HHS enforcement-discretion policy from October 2026 covers each peptide only as a single active ingredient, so blends fall outside it.[1]
Sources
- Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (91 FR 68526)
- FDA briefing document: BPC-157-related bulk drug substances
- FDA briefing document: TB-500-related bulk drug substances
- Lee E, Padgett B. Intra-articular BPC-157 for knee pain: retrospective review (Altern Ther Health Med 2021;27(4):8–13)
- World Anti-Doping Code: Prohibited List 2026
- Warning letter: Warrior Labz SARMS
- Certain bulk drug substances for use in compounding that may present significant safety risks